Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) insider Vidya Raman-Tangella sold 1,537 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $7.33, for a total value of $11,266.21. Following the completion of the sale, the insider now owns 32,130 shares of the company’s stock, valued at $235,512.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Vidya Raman-Tangella also recently made the following trade(s):
- On Friday, August 2nd, Vidya Raman-Tangella sold 3,857 shares of Teladoc Health stock. The shares were sold at an average price of $8.14, for a total transaction of $31,395.98.
- On Monday, June 3rd, Vidya Raman-Tangella sold 1,122 shares of Teladoc Health stock. The stock was sold at an average price of $11.16, for a total transaction of $12,521.52.
Teladoc Health Price Performance
NYSE:TDOC opened at $7.22 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66. The company has a 50-day moving average of $9.57 and a 200-day moving average of $13.34. Teladoc Health, Inc. has a 52 week low of $7.14 and a 52 week high of $25.84. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -5.12 and a beta of 0.93.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several research analysts recently commented on the stock. Royal Bank of Canada dropped their target price on shares of Teladoc Health from $25.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, April 26th. TD Cowen cut their price objective on Teladoc Health from $15.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, August 1st. Bank of America decreased their target price on Teladoc Health from $16.50 to $13.50 and set a “neutral” rating for the company in a research note on Tuesday, May 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. reduced their price objective on Teladoc Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday, May 21st. Fourteen analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $13.56.
Check Out Our Latest Research Report on TDOC
Teladoc Health Company Profile
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Further Reading
- Five stocks we like better than Teladoc Health
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- It’s Too Soon to Buy the Dip in Weight Loss Drugmakers
- What Are the U.K. Market Holidays? How to Invest and Trade
- Owens-Corning Stock: Good Value or Recession Red Flag?
- What does consumer price index measure?
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.